Clinical Trial Update: A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) [Phase 2]

View source ↗

Summary

A Phase 2 multicenter study evaluating STN1010904 ophthalmic suspension (0.03% and 0.1%) versus vehicle in Fuchs Endothelial Corneal Dystrophy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fuchs Endothelial Corneal Dystrophy

Drugs mentioned

• STN1010904 ophthalmic suspension 0.03% and 0.1%

Snippet

Sponsor: Santen Inc. | Conditions: Fuchs Endothelial Corneal Dystrophy | Phase 2 | Status: COMPLETED